Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Fresenius Medical Care AG & Co. KGAA
Type
Kommanditgesellschaft auf Aktien with Aktiengesellschaft as partner with unlimited liability
Traded as FWB: FME
NYSE: FMS
Industry Health care
Founded 1996
Headquarters Bad Homburg, Germany
Key people
Rice Powell (CEO and Chairman of the executive board), Michael Brosnan (CFO), Roberto Fusté (Chief Executive Officer for Asia-Pacific), Dr. Emanuele Gatti (Chief Executive Officer for Europe, Middle East, Africa and Latin America), Ronald Kuerbitz (Chief Executive Officer for North America), Gerd Krick (Chairman of the supervisory board)
Products Kidney dialysis products and services, Therapuetic Aphoresis Products
Revenue US $14.6 billion (2013)
Operating income
US $2,256 million (2013)
Profit US $1,110 million (2013)
Total assets US $22.120 billion (end 2013)
Total equity US $9.485 billion (end 2013)
Number of employees
90,690 (FTE, end 2013)
Website www.freseniusmedicalcare.com

Fresenius Medical Care is a German company specializing in the production of medical supplies, primarily to facilitate or aid renal dialysis. It is 30% owned by the health care company Fresenius. As of December 31, 2015, the number of Fresenius Medical Care shares held by its largest shareholder, Fresenius SE & Co. KGaA remained unchanged at around 94.4 M. This corresponds to a 30.9% interest in its share capital.

Fresenius Medical Care operates more than 40 production sites on all continents. Its largest plants in terms of production output are in the U.S. (Ogden, Utah, and Concord, California), Germany (Schweinfurt and St. Wendel), and Japan (Buzen). These plants are categorized as large and small with 25 large facilities and 15 small ones worldwide which cater to local demand for dialysis products. Plants that fall under the concentrates division, manufacture finished products from raw materials, such as sodium chloride, dextrose, and magnesium, to name a few. Raw materials go through a complex mixing and packaging process.

Fresenius Medical Care manufactures a variety of durable medical devices used in the treatment of End Stage Renal Disease (ESRD). Devices include Hemodialysis Machines, Peritoneal Dialysis Machines, Granuflo Concentrate Mixing Tanks and monitoring devices including the Crit-line device. The dialysis machines are manufactured in one of two plants to serve the globe. These plants are located in Schweinfurt, Germany and Concord, California. Crit-line devices are manufactured in Concord, California.

Distribution is where the finished product, from Manufacturing, comes in on Semi-Trucks to be distributed to dialysis clinics, hospitals, and home dialysis patients. These products are then used in the dialysis process.

On 30 October 2006, the manufacturing facility (Fresenius Hemocare) in Redmond, Washington was shut down. Fresenius Hemocare has stopped going by the name Fresenius Hemocare and now goes by the name Fresenius-Kabi LLC. The closing of one of two entities inside of Hemocare allowed for the name change and takes Hemocare from the Medical Care group to the Kabi group.

In 2012, Fresenius acquired Liberty Dialysis Holdings, in a deal which entailed the sale of its outpatient dialysis clinics in 43 local markets within the U.S.

In 2013, Fresenius Medical Care NA acquired Shiel Medical Laboratory Inc, expanding services to New York City metro area.

Fresenius Medical Care Renal Services Limited runs 54 dialysis units across England and more across Wales. In September 2014 new renal dialysis units run by Fresenius were opened at Withybush General Hospital and West Wales General Hospital, with a contract to run for at least 7 years.

In August 2017, Fresenius acquired NxStage Medical, a medical device manufacturer based in Lawrence, Massachusetts for a reported $2 billion dollars.

Investment goal date:
Dividends reinvested
Fresenius Medical Care AG & Co. KGAA FMS report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-03
--
--
Q4 2017
2018-02-27
--
--
Q3 2017
2017-11-02
--
--
Q3 2017
2017-11-02
0.5900
0.0000
Q2 2017
2017-08-01
0.4800
0.5200
Q1 2017
2017-05-03
0.5300
0.5300
Q4 2016
2017-02-22
0.6400
0.6300
Q3 2016
2016-10-27
0.5400
0.5500
Q2 2016
2016-08-02
0.4800
0.4800
Q1 2016
2016-05-03
0.3700
0.3800
Q4 2015
2016-02-24
0.5200
0.5200
Q3 2015
2015-10-29
0.4300
0.4300
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BANK OF AMERICA CORP /DE/
1493411
CAMBIAR INVESTORS LLC
2516416
GOLDMAN SACHS GROUP INC
204051
HARDING LOEVNER LP
3528960
Jarislowsky, Fraser Ltd
292920
Karp Capital Management Corp
187208
MANAGED ACCOUNT ADVISORS LLC
296428
MANNING & NAPIER ADVISORS LLC
280215
MARATHON ASSET MANAGEMENT LLP
630548
MORGAN STANLEY
711099
NORTHERN TRUST CORP
938840
PARAMETRIC PORTFOLIO ASSOCIATES LLC
304370
ROYAL BANK OF CANADA
471575
US BANCORP \DE\
386900
WELLS FARGO & CO/MN
271969
Major Shareholders
Name Relationship
Total Shares
Holding stocks